200 - 3650 GILMORE WAY, BURNABY, A1
Announces Annual Meeting of Shareholders
Xenon Pharmaceuticals Enters Underwriting Agreement for Public Offering
Investor Presentation
Xenon Pharmaceuticals Files $400 Million Prospectus Supplement
Reports Q4 and Full Year 2025 Financial Results and Provides Business Update
Xenon Pharmaceuticals Increases Share Reserve in 2025 Inducement Plan
Reports Third Quarter 2025 Financial Results & Business Update
Amended material disclosure
FY 2024
Q3
Q2
Q1
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Free Writing Prospectus
Confidential Treatment Order
Correspondence